Liam T. Gaynor, Ph.D.

Patent Agent

+1 617 646 1662 +1 617 646 1662
liam.gaynor@finnegan.com liam.gaynor@finnegan.com

Two Seaport Lane
Boston, MA 02210-2001

vCard

Show Liam's work in

Liam Gaynor, Ph.D., applies his extensive technical background in cancer biology, epigenetics, and computational biology to patent prosecution matters within the biotechnology field.

Prior to joining Finnegan, Liam obtained his doctorate through the Biological and Biomedical Sciences program at Harvard University. His dissertation research performed at Dana Farber Cancer Institute examined the progression from the initial acquisition of a mutation to the emergence of intestinal tumors, employing high throughput sequencing techniques, fluorescent microscopy imaging, organoid cell culture, and Monte Carlo simulations. As an undergraduate at the University of North Carolina at Chapel Hill, Liam performed research focused on intestinal organoid technology development.

Et Cetera

Coauthor. “Crypt density and recruited enhancers underlie intestinal tumour initiation,” Nature, 640, 231-239, 2025.
Coauthor. "Distinct Mesenchymal Cell Populations Generate the Essential BMP Signaling Gradient," Cell Stem Cell, 2020.
Coauthor. "Ketone Body Signaling Mediates Intestinal Stem Cell Homeostasis and Adaptation to Diet," Cell, 2019.
Coauthor. "A High-Throughput Organoid Microinjection Platform to Study Gastrointestinal Microbiota and Luminal Physiology," Cellular and Molecular Gastroenterology and Hepatology (CMGH), 2018.
Coauthor. "A high-throughput platform for stem cell niche co-cultures and downstream gene expression analysis," Nature Cell Biology, 2015.

Experience

Comprehensive patent transactions and strategic counseling for one of the largest pharmaceutical companies in the world

Finnegan is lead and preferred IP transactions counsel for one of the largest pharmaceutical companies in the world, handling more than 50 diligence projects each year, including all IP and related transactional aspects of the matters. The transactions span the full gamut of technologies from small molecule through biologics such as antibodies, oligonucleotides, and gene therapies. Finnegan also provides extensive assistance with post-deal integration procedures and subsequent global prosecution and portfolio strategy, ensuring a seamless transition of IP assets to the company and maximum value from acquired IP.

Admissions and Education

Admissions

U.S. Patent and Trademark Office

Education

Harvard University: Ph.D., Biological and Biomedical Sciences, 2023

University of North Carolina at Chapel Hill: B.S., Biology, 2016

University of North Carolina at Chapel Hill: B.A., Math, 2016

Liam's Practices

Prosecution and Portfolio Management: Opinions and Counseling; Patent Drafting and Prosecution

Liam's Industries

Life Sciences: Biologics; Biotechnology